[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100410056":3},{"organization":4,"armGroups":7,"interventions":19,"overallOfficials":30,"centralContacts":35,"locations":45,"responsibleParty":89,"collaborators":91,"id":94,"slug":95,"hasResults":96,"nctId":97,"briefTitle":98,"officialTitle":99,"acronym":100,"eligibilityCriteria":101,"healthyVolunteers":96,"sex":102,"minAge":25,"maxAge":103,"enrollmentInfo":104,"targetDuration":25,"studyType":107,"phases":108,"briefSummary":110,"conditions":111,"keywords":116,"overallStatus":48,"whyStopped":25,"lastUpdateSubmitDate":126,"lastUpdatePostDateStruct":127,"startDateStruct":130,"completionDateStruct":132,"leadSponsor":134,"locationsCount":135},{"fullName":5,"class":6},"The Institute of Molecular and Translational Medicine, Czech Republic","OTHER",[8,14],{"label":9,"type":10,"description":11,"interventionNames":12},"A: Patients undergo cycle with the transfer of fresh embryos","EXPERIMENTAL","In study group A the cervical mucus will be collected from patients undergoing the in vitro fertilisation (IVF)\u002Fintracytoplasmic sperm injection (ICSI)\u002Fembryo transfer (ET) cycle with the transfer of fresh embryos.",[13],"Diagnostic Test: Cervical mucus will be collected from patients undergoing IVF",{"label":15,"type":10,"description":16,"interventionNames":17},"B: Patients undergo cycle with the transfer of frozen embryos","In study group B cervical mucus will be sampled from patients undergoing treatment cycles with the transfer of cryopreserved embryos.",[18],"Diagnostic Test: Cervical mucus will be collected from patients undergoing transfer of cryopreserved embryos",[20,26],{"type":21,"name":22,"description":23,"armGroupLabels":24,"otherNames":25},"DIAGNOSTIC_TEST","Cervical mucus will be collected from patients undergoing IVF","Patients undergoing hormonal stimulation for IVF will be sampled for cervical mucus.",[9],null,{"type":21,"name":27,"description":28,"armGroupLabels":29,"otherNames":25},"Cervical mucus will be collected from patients undergoing transfer of cryopreserved embryos","Patients undergoing hormonal substitution for transfer of cryopreserved embryos will be sampled for cervical mucus.",[15],[31],{"name":32,"affiliation":33,"role":34},"Marian Hajduch, MD.PhD.","Palacky University in Olomouc, Faculty of Medicine and Dentristry","STUDY_DIRECTOR",[36,41],{"name":37,"role":38,"phone":39,"phoneExt":25,"email":40},"Radovan Pilka, Prof.MD.PhD.","CONTACT","+420739329868","radovan.pilka@fnol.cz",{"name":42,"role":38,"phone":43,"phoneExt":25,"email":44},"Petr Dzubak, MD.PhD.","+420604851158","dzubakp@gmail.com",[46,64,82],{"facility":47,"status":48,"city":49,"state":50,"zip":51,"country":52,"countryCode":25,"cosmosGeoPoint":53,"geoPoint":58,"contacts":59},"Brno University Hospital","RECRUITING","Brno","South Moravian","62500","Czechia",{"type":54,"coordinates":55},"Point",[56,57],16.60796,49.19522,{"lat":57,"lon":56},[60],{"name":61,"role":38,"phone":62,"phoneExt":25,"email":63},"Igor Crha, MD, PhD","+420728159163","crha.igor@fnbrno.cz",{"facility":65,"status":48,"city":66,"state":25,"zip":67,"country":52,"countryCode":25,"cosmosGeoPoint":68,"geoPoint":72,"contacts":73},"University Hospital Olomouc","Olomouc","77900",{"type":54,"coordinates":69},[70,71],17.25175,49.59552,{"lat":71,"lon":70},[74,78],{"name":75,"role":38,"phone":76,"phoneExt":25,"email":77},"Petr Dzubak, MD, PhD","+420 585632150","petr.dzubak@upol.cz",{"name":79,"role":38,"phone":80,"phoneExt":25,"email":81},"Marian Hadjuch, MD, PhD","+420 585632082","marian.hajduch@upol.cz",{"facility":65,"status":48,"city":66,"state":25,"zip":25,"country":52,"countryCode":25,"cosmosGeoPoint":83,"geoPoint":85,"contacts":86},{"type":54,"coordinates":84},[70,71],{"lat":71,"lon":70},[87],{"name":88,"role":38,"phone":39,"phoneExt":25,"email":40},"Radovan Pilka, Prof.MD.",{"type":90,"investigatorFullName":25,"investigatorTitle":25,"investigatorAffiliation":25,"oldNameTitle":25,"oldOrganization":25},"SPONSOR",[92,93],{"name":65,"class":6},{"name":47,"class":6},"100410056","biomarkers-of-endometrial-receptivity-100410056",false,"NCT04619524","Biomarkers of Endometrial Receptivity","Biomarkers of Endometrial Receptivity: A Prospective Multicenter Study on Proteomic Biomarkers of Endometrial Receptivity in Cervical Mucus ( PRO BIOMER - CM )","BIOMER","Inclusion Criteria - Arm A - stimulated cycle:\n\n* female aged less than 37 years (maximally 36y + 364d)\n* no smoker\n* normal menstrual cycles lasting between 25 to 35 days\n* had been infertile for less than five years\n* normal responder\n* fewer than three failed cycles of assisted reproduction treatment, including fresh IVF\u002F intracytoplasmic sperm injection (ICSI) embryo transfer cycles and\u002For frozen-thawed embryo transfer cycles\n* sperm obtained through ejaculation\n* spermiogram more than 5 million sperm\u002FmL\n* BMI 19-29 kg\u002Fm2\n* follicle stimulating hormone (FSH) \\\u003C 10 IU\u002FL on the third day\n* basal antral follicle count of 5-15\n* undergoing the same routine gonadotrophin-releasing hormone agonist (GnRHa) long depot or gonadotrophin-releasing hormone antagonist (GnRH-ant.) protocol\n* informed consent\n\nExclusion Criteria - Arm A - stimulated cycle:\n\n* genetic disease\n* metabolic and\u002For endocrine disorders\n* polycystic ovary syndrome (defined by the Rotterdam criteria)\n* women with prior diagnosis of endometriosis or adenomyosis\n* previous gynecological\u002Fpelvic surgery except for salpingectomy\n* repeated spontaneous abortions (two or more)\n* previously less than 5 oocytes and\u002For serum anti-Mullerian hormone value \\\u003C 1.0 mIU\u002Fml or more than 20 oocytes, milli-International unit (mIU)\n* previous ovarian hyperstimulation syndrome (OHSS)\n* presence of any structural abnormality of the reproductive system\n* donor oocyte cycles\n* severe male factor infertility \\\u003C 5 million sperm\u002FmL\n* low response to stimulation\n* endometrium \\\u003C 8 mm at the day of human chorionic gonadotropin (hCG) or ET\n* number of retrieved oocytes 5 - 20\n* low fertilization capacity (rate of fertilization \\\u003C 20% and late ICSI following IVF fertilization failure)\n* OHSS\n* IVF cycle cancelled before ET\n* other than easy one high-quality blastocyst transfer (at least grade 3BB)\n\nInclusion criteria - Arm B - substituted cycle:\n\n* female aged less than 37 years (maximally 36y + 364d)\n* no smoker\n* normal menstrual cycles lasting between 25 to 35 days\n* had been infertile for less than five years\n* normal responder at stimulation\n* fewer than three failed cycles of assisted reproduction treatment, including fresh IVF\u002F intracytoplasmic sperm injection (ICSI) embryo transfer cycles and\u002For frozen-thawed embryo transfer cycles\n* sperm obtained through ejaculation\n* spermiogram more than 5 million sperm\u002FmL\n* BMI 19-29 kg\u002Fm2\n* FSH \\\u003C 10 IU\u002FL on the third day\n* undergoing the same routine estrogen\u002Fprogesterone substituted cycle\n* informed consent\n\nExclusion criteria - Arm B - substituted cycle:\n\n* genetic disease\n* metabolic and\u002For endocrine disorders such as diabetes, metabolic syndrome, and thyroid disorders\n* polycystic ovary syndrome (defined by the Rotterdam criteria), hyperprolactinaemia\n* women with prior diagnosis of endometriosis or adenomyosis\n* previous gynecological\u002Fpelvic surgery except for salpingectomy\n* repeated spontaneous abortions (two or more)\n* previously less than 5 oocytes and\u002For serum anti-Mullerian hormone value \\\u003C 0.5 mIU\u002Fml in the stimulated cycle\n* previous OHSS\n* presence of any structural abnormality of the reproductive system\n* severe male factor infertility \\\u003C 5 million sperm\u002FmL in the stimulated cycle\n* number of retrieved oocytes 5 - 20 in the stimulated cycle\n* low fertilization capacity (rate of fertilization \\\u003C 20% and late ICSI following IVF fertilization failure)\n* endometrium less than 8 mm at the day of thawing and transfer indication\n* thawed blastocyst cycle cancelled before ET\n* other than easy one best quality frozen\u002Fthawed blastocyst transfer (at least grade 3BB)","FEMALE","36 Years",{"count":105,"type":106},476,"ESTIMATED","INTERVENTIONAL",[109],"NA","Analysis of proteins from cervical mucus will be done in patients undergoing infertility treatment (fresh or frozen embryo transfer). Cervical mucus will be analysed for potential new biomarkers of endometrium receptivity. Comparison of the peptide spectrum will be done for the pregnant and not pregnant patients.",[112,113,114,115],"IVF","Infertility Treatment","Fertility Disorders","Embryo Transfer",[117,118,119,120,121,122,123,124,125],"cervix","mucus","endometrium","receptivity","biomarker","proteomics","infertility","in-vitro","fertilisation","2026-03-19",{"date":128,"type":129},"2026-03-20","ACTUAL",{"date":131,"type":129},"2018-05-01",{"date":133,"type":106},"2026-12-31",{"name":5,"class":6},3]